Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
DEMYELINATING DISEASES: Edited by Hans-Peter Hartung

Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm

Cree, Bruce A.C.a; Mares, Janb; Hartung, Hans-Peterc

Author Information
Current Opinion in Neurology: June 2019 - Volume 32 - Issue 3 - p 365-377
doi: 10.1097/WCO.0000000000000700

Abstract

Erratum

Figure 7 in the article, ‘Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm’ which published in the June 2019 issue of Current Opinion in Neurology, included an error .

Authors confirmed Ozanimod had no impact on EDSS in either SUNBEAM or RADIANCE. The correct text from the figure should read: “A significant reduction in risk of 3m-CDP vs. IFN β-1a was not reached in the pooled analysis of SUNBEAM and RADIANCE studies.”

5+ images

Current Opinion in Neurology. 32(5):782, October 2019.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.